Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Clinical trial NCT00228358 · COMPLETED

Trial details

NCT number: NCT00228358
Sponsor: University of Washington
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

HER2-positive Breast Cancer Recurrent Breast Cancer Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Ovarian Germ Cell Tumor Stage IV Breast Cancer Stage IV Non-small Cell Lung Cancer Stage IV Ovarian Epithelial Cancer Stage IV Ovarian Germ Cell Tumor

Start date: 2003-06-01
Primary completion: 2011-05-01
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.